Elevance Health Inc
ELV: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$444.00 | Jvfxgd | Ztwfzqyxv |
Elevance Earnings: Medicaid Weakness Offset on Bottom Line, and 2024 Guidance Remains Solid
Narrow-moat Elevance delivered slightly higher fourth-quarter results and 2024 guidance than we were expecting, despite rising medical utilization trends. However, our long-term forecasts and $520 fair value estimate have not changed materially, and recent trades look close to fair value.